Critical Analysis: AIM ImmunoTech (NYSE:AIM) & Protalix BioTherapeutics (NYSE:PLX)

Protalix BioTherapeutics (NYSE:PLX) and AIM ImmunoTech (NYSE:AIM) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, profitability, dividends, risk and earnings.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Protalix BioTherapeutics and AIM ImmunoTech, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protalix BioTherapeutics	0	0	1	0	3.00
AIM ImmunoTech	0	0	2	0	3.00

Protalix BioTherapeutics presently has a consensus target price of $15.00, suggesting a potential upside of 772.09%. AIM ImmunoTech has a consensus target price of $275.00, suggesting a potential upside of 10,600.39%. Given AIM ImmunoTech’s higher probable upside, analysts clearly believe AIM ImmunoTech is more favorable than Protalix BioTherapeutics.

Volatility and Risk

Protalix BioTherapeutics has a beta of -0.23, indicating that its share price is 123% less volatile than the S&P 500. Comparatively, AIM ImmunoTech has a beta of 0.98, indicating that its share price is 2% less volatile than the S&P 500.

Valuation & Earnings

This table compares Protalix BioTherapeutics and AIM ImmunoTech”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protalix BioTherapeutics	$61.95 million	2.21	$8.31 million	$0.07	24.57
AIM ImmunoTech	$121,000.00	57.54	-$28.96 million	($24.68)	-0.10

Protalix BioTherapeutics has higher revenue and earnings than AIM ImmunoTech. AIM ImmunoTech is trading at a lower price-to-earnings ratio than Protalix BioTherapeutics, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

16.5% of Protalix BioTherapeutics shares are held by institutional investors. Comparatively, 12.0% of AIM ImmunoTech shares are held by institutional investors. 6.5% of Protalix BioTherapeutics shares are held by insiders. Comparatively, 0.0% of AIM ImmunoTech shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Protalix BioTherapeutics and AIM ImmunoTech’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Protalix BioTherapeutics	-21.03%	-30.89%	-11.74%
AIM ImmunoTech	-12,594.21%	-421.73%	-147.54%

Summary

Protalix BioTherapeutics beats AIM ImmunoTech on 8 of the 13 factors compared between the two stocks.

About Protalix BioTherapeutics

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.

About AIM ImmunoTech

AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat human papilloma viruses, and genital warts, a sexually transmitted disease. AIM ImmunoTech Inc. has agreements with Amarex Clinical Research LLC; University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente; Jubilant HollisterStier; Sterling Pharma Solutions; Erasmus University Medical Center Rotterdam; Azenova, LLC; and Alcami Corporation. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.